HighTower Advisors LLC lessened its holdings in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 0.4% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,958,587 shares of the company’s stock after selling 8,756 shares during the quarter. HighTower Advisors LLC’s holdings in AbbVie were worth $512,347,000 at the end of the most recent quarter.
A number of other large investors have also modified their holdings of ABBV. Presper Financial Architects LLC acquired a new stake in AbbVie in the 3rd quarter valued at about $457,000. Western Wealth Management LLC boosted its holdings in shares of AbbVie by 2.4% during the 3rd quarter. Western Wealth Management LLC now owns 38,339 shares of the company’s stock worth $10,029,000 after purchasing an additional 899 shares during the last quarter. Francis Financial Inc. boosted its holdings in shares of AbbVie by 13.9% during the 3rd quarter. Francis Financial Inc. now owns 1,274 shares of the company’s stock worth $333,000 after purchasing an additional 155 shares during the last quarter. Intech Investment Management LLC grew its position in shares of AbbVie by 9.8% in the third quarter. Intech Investment Management LLC now owns 50,653 shares of the company’s stock valued at $13,250,000 after purchasing an additional 4,505 shares in the last quarter. Finally, Bridgewealth Advisory Group LLC grew its position in shares of AbbVie by 6.1% in the third quarter. Bridgewealth Advisory Group LLC now owns 1,248 shares of the company’s stock valued at $326,000 after purchasing an additional 72 shares in the last quarter. Hedge funds and other institutional investors own 70.23% of the company’s stock.
AbbVie Stock Performance
ABBV opened at $294.18 on Tuesday. The stock has a market capitalization of $520.00 billion, a PE ratio of 50.63, a P/E/G ratio of 1.34 and a beta of 0.20. AbbVie Inc. has a one year low of $190.75 and a one year high of $302.93. The business’s 50 day moving average price is $276.27 and its 200 day moving average price is $241.28.
AbbVie (NYSE:ABBV – Get Free Report) last posted its earnings results on Friday, October 30th. The company reported $3.82 EPS for the quarter, beating analysts’ consensus estimates of $3.73 by $0.09. AbbVie had a negative return on equity of 450.55% and a net margin of 15.67%. The company had revenue of $17.40 billion for the quarter, compared to the consensus estimate of $17.32 billion. During the same quarter in the previous year, the business earned $1.86 earnings per share. The company’s revenue for the quarter was up 10.3% on a year-over-year basis. As a group, equities research analysts forecast that AbbVie Inc. will post 13.98 earnings per share for the current fiscal year.
AbbVie Increases Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 16th. Investors of record on Friday, January 15th will be issued a $1.82 dividend. This is an increase from AbbVie’s previous quarterly dividend of $1.73. The ex-dividend date is Friday, January 15th. This represents a $7.28 annualized dividend and a yield of 2.5%. AbbVie’s payout ratio is presently 125.30%.
Insider Transactions at AbbVie
In other AbbVie news, EVP Jeffrey Stewart sold 40,619 shares of the company’s stock in a transaction dated Monday, November 9th. The shares were sold at an average price of $293.60, for a total value of $11,925,738.40. Following the transaction, the executive vice president owned 83,171 shares of the company’s stock, valued at $24,419,005.60. This represents a 32.81% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Company insiders own 0.06% of the company’s stock.
Analysts Set New Price Targets
Several equities research analysts recently commented on the company. HSBC increased their price target on AbbVie from $300.00 to $315.00 and gave the company a “buy” rating in a report on Thursday, September 10th. Erste Group Bank upgraded AbbVie from a “hold” rating to a “buy” rating in a report on Wednesday, August 5th. BNP Paribas Exane raised their target price on AbbVie from $218.00 to $247.00 and gave the stock a “neutral” rating in a research note on Tuesday, August 11th. Bank of America reiterated a “buy” rating on shares of AbbVie in a report on Tuesday, September 8th. Finally, Sanford C. Bernstein reissued a “market perform” rating and issued a $275.00 price objective on shares of AbbVie in a report on Monday, November 2nd. One analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $297.85.
Get Our Latest Analysis on AbbVie
AbbVie Profile
AbbVie is a biopharmaceutical company that discovers, develops and markets medicines for a range of serious health conditions. Its research and product portfolio spans immunology, oncology, neuroscience and other therapeutic areas. Key products include the immunology medicines Skyrizi and Rinvoq, cancer treatments such as Imbruvica and Venclexta, and neuroscience therapies including Botox and Vraylar. Through its Allergan acquisition, AbbVie also offers aesthetics products such as Botox Cosmetic and Juvéderm.
Further Reading
- Five stocks we like better than AbbVie
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV – Free Report).
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.
